Analytical Data
-
Gene name
TRAF2
- Application
-
Alternative Names
TRAP; TRAP3; E3 ubiquitin-protein ligase TRAF2; Tumor necrosis factor type 2 receptor-associated protein 3
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P39429
-
Expression Region
Gln238~Phe491
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TRAF2 (TNF Receptor-Associated Factor 2) is a crucial adaptor protein involved in the signaling pathways of various receptors, particularly those belonging to the tumor necrosis factor (TNF) receptor superfamily. It plays a pivotal role in mediating cellular responses to inflammation, immunity, and apoptosis. The study of TRAF2 has garnered significant attention due to its implications in various diseases, including cancer, autoimmune disorders, and inflammatory conditions. Dysregulation of TRAF2 signaling has been linked to the progression of multiple malignancies, making it a potential target for therapeutic interventions. Given its multifaceted roles, researchers have been exploring the biochemical and structural aspects of TRAF2 to understand how it interacts with other proteins and modulates signaling pathways. The production of TRAF2 recombinant proteins has facilitated the study of its functional properties, interaction networks, and the development of TRAF2 inhibitors or modulators. Continued research on TRAF2 not only enhances our understanding of its biological functions but also holds promise for the development of novel therapeutic strategies against various diseases associated with TRAF2 dysregulation.
